Hot needles can confirm accurate lesion sampling intraoperatively using [18F]PSMA-1007 PET/CT-guided biopsy in patients with suspected prostate cancer.
Purpose: Prostate-specific membrane antigen (PSMA)-targeted PET is increasingly used for staging prostate cancer (PCa) with high accuracy to detect significant PCa (sigPCa). [68 Ga]PSMA-11 PET/MRI-guided biopsy showed promising results but also persisting limitation of sampling error, due to impaire...
| Publicado en: | European Journal of Nuclear Medicine & Molecular Imaging Vol. 49; no. 5; pp. 1721 - 1731 |
|---|---|
| Autores principales: | , , , , , , , , , , , , |
| Formato: | clinical trial diagnostic images pictorial research tables/charts Journal Article |
| Publicado: |
Springer Nature
Apr2022
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=155912913&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 155912913 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 16197070 NPC jtl: European Journal of Nuclear Medicine & Molecular Imaging issn: 16197070 maglogo: N pubinfo: dt: Apr2022 vid: 49 iid: 5 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 155912913 153333824 155912913 155912913 10.1007/s00259-021-05599-3 155912913 ppf: 1721 ppct: 10 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Hot needles can confirm accurate lesion sampling intraoperatively using [18F]PSMA-1007 PET/CT-guided biopsy in patients with suspected prostate cancer. aug: au: Ferraro, Daniela A. Laudicella, Riccardo Zeimpekis, Konstantinos Mebert, Iliana Müller, Julian Maurer, Alexander Grünig, Hannes Donati, Olivio Sapienza, Marcelo T. Rueschoff, Jan H. Rupp, Niels Eberli, Daniel Burger, Irene A. affil: Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland sug: subj: Needles Intraoperative Period Positron-Emission Tomography Tomography, X-Ray Computed Biopsy Prostatic Neoplasms Diagnosis Prostate-Specific Membrane Antigen Human Prospective Studies Spectrometry, gamma Pearson's Correlation Coefficient Immunohistochemistry ROC Curve Nonrandomized Trials Clinical Trials Descriptive Statistics ab: Purpose: Prostate-specific membrane antigen (PSMA)-targeted PET is increasingly used for staging prostate cancer (PCa) with high accuracy to detect significant PCa (sigPCa). [68 Ga]PSMA-11 PET/MRI-guided biopsy showed promising results but also persisting limitation of sampling error, due to impaired image fusion. We aimed to assess the possibility of intraoperative quantification of [18F]PSMA-1007 PET/CT uptake in core biopsies as an instant confirmation for accurate lesion sampling. Methods: In this IRB-approved, prospective, proof-of-concept study, we included five consecutive patients with suspected PCa. All underwent [18F]PSMA-1007 PET/CT scans followed by immediate PET/CT-guided and saturation template biopsy (3.1 ± 0.3 h after PET). The activity in biopsy cores was measured as counts per minute (cpm) in a gamma spectrometer. Pearson's test was used to correlate counts with histopathology (WHO/ISUP), tumor length, and membranous PSMA expression on immunohistochemistry (IHC). Results: In 43 of 113 needles, PCa was present. The mean cpm was overall significantly higher in needles with PCa (263 ± 396 cpm) compared to needles without PCa (73 ± 44 cpm, p < 0.001). In one patient with moderate PSMA uptake (SUVmax 8.7), 13 out of 24 needles had increased counts (100–200 cpm) but only signs of inflammation and PSMA expression in benign glands on IHC. Excluding this case, ROC analysis resulted in an AUC of 0.81, with an optimal cut-off to confirm PCa at 75 cpm (sens/spec of 65.1%/87%). In all 4 patients with PCa, the first or second PSMA PET-guided needle was positive for sigPCa with high counts (156–2079 cpm). Conclusions: [18F]PSMA-1007 uptake in PCa can be used to confirm accurate lesion sampling of the dominant tumor intraoperatively. This technique could improve confidence in imaging-based biopsy guidance and reduce the need for saturation biopsy. Trial registration number: NCT03187990, 15/06/2017. pubtype: Academic Journal doctype: clinical trial diagnostic images pictorial research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|